Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Non-Current Debt (2016 - 2025)

Cytokinetics (CYTK) has disclosed Non-Current Debt for 12 consecutive years, with $246.4 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt changed N/A to $246.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $246.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $246.4 million for FY2025, N/A changed from the prior year.
  • Non-Current Debt for Q4 2025 was $246.4 million at Cytokinetics, up from $158.7 million in the prior quarter.
  • The five-year high for Non-Current Debt was $246.4 million in Q4 2025, with the low at $30.2 million in Q3 2021.
  • Average Non-Current Debt over 5 years is $81.6 million, with a median of $62.5 million recorded in 2023.
  • The sharpest move saw Non-Current Debt tumbled 34.23% in 2021, then surged 110.39% in 2022.
  • Over 5 years, Non-Current Debt stood at $47.4 million in 2021, then soared by 34.71% to $63.8 million in 2022, then fell by 8.5% to $58.4 million in 2023, then surged by 59.32% to $93.0 million in 2024, then soared by 164.88% to $246.4 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $246.4 million, $158.7 million, and $159.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.